514
Participants
Start Date
July 22, 2020
Primary Completion Date
November 1, 2021
Study Completion Date
November 1, 2021
TNX-102 SL
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
Placebo SL Tablet
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
Tonix Clinical Site, Williamsville
Tonix Clinical Site, Charlottesville
Tonix Clinical Site, High Point
Tonix Clinical Site, Raleigh
Tonix Clinical Site, Alpharetta
Tonix Clinical Site, Jacksonville
Tonix Clinical Site, Temecula
Tonix Clinical Site, Orlando
Tonix Clinical Site, North Miami
Tonix Clinical Site, Fort Myers
Tonix Clinical Site, Ocala
Tonix Clinical Site, Birmingham
Tonix Clinical Site, Chattanooga
Tonix Clinical Site, Memphis
Tonix Clinical Site, North Canton
Tonix Clinical Site, Cincinnati
Tonix Clinical Site, Dayton
Tonix Clinical Site, Evansville
Tonix Clinical Site, West Des Moines
Tonix Clinical Site, Kenosha
Tonix Clinical Site, Prairie Village
Tonix Clinical Site, New Orleans
Tonix Clinical Site, Oklahoma City
Tonix Clinical Site, Tulsa
Tonix Clinical Site, Dallas
Tonix Clinical Site, Austin
Tonix Clinical Site, Salt Lake City
Tonix Clinical Site, Phoenix
Tonix Clinical Site, Albuquerque
Tonix Clinical Site, Oceanside
Tonix Clinical Site, San Diego
Tonix Clinical Site, Santa Ana
Tonix Clinical Site, Portland
Tonix Clinical Site, Cromwell
Tonix Clinical Site, Boston
Tonix Clinical Site, Warwick
Tonix Pharmaceuticals, Inc.
INDUSTRY